Achillion Pharmaceuticals, Inc. (ACHN) Misses Q4 EPS by 2c; Guides FY12
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Join SI Premium – FREE
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) reported Q4 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $120 thousand.
Sees FY2012 EPS of $-0.65-$-0.70, versus the consensus of $-0.64.
For earnings history and earnings-related data on Achillion Pharmaceuticals, Inc. (ACHN) click here.
Sees FY2012 EPS of $-0.65-$-0.70, versus the consensus of $-0.64.
For earnings history and earnings-related data on Achillion Pharmaceuticals, Inc. (ACHN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Vireo Growth completes acquisition of C21 Investments
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
